BACKGROUND: The poor outcomes in patients with acute kidney injury (AKI) and end-stage renal disease (ESRD) on chronic dialysis are due to immune dysregulation associated with these disorders. Evolving evidence suggests that the kidney, and specifically renal epithelial cells, plays an important role in the immunological response of leukocytes under disease states. METHOD: In this regard, the development of two therapeutic approaches utilizing renal epithelial cells and 'smart' immunomodulatory membranes has been tested in preclinical animal models and clinical trials. RESULTS: These two approaches have been demonstrated in phase II human trials to improve the survival of intensive care unit patients with AKI and multiorgan failure. The use of a 'smart' immunomodulatory membrane is also being evaluated in a small exploratory clinical trial to assess its effects on immunoregulation in ESRD patients requiring chronic hemodialysis. CONCLUSIONS: The use of renal progenitor/stem cell therapy and/or cytopheretic membranes may result in effective treatments to alter the dysregulated immunological state of acute or chronic renal failure and improve the outcomes of these diseases. Copyright (c) 2010 S. Karger AG, Basel.
RCT Entities:
BACKGROUND: The poor outcomes in patients with acute kidney injury (AKI) and end-stage renal disease (ESRD) on chronic dialysis are due to immune dysregulation associated with these disorders. Evolving evidence suggests that the kidney, and specifically renal epithelial cells, plays an important role in the immunological response of leukocytes under disease states. METHOD: In this regard, the development of two therapeutic approaches utilizing renal epithelial cells and 'smart' immunomodulatory membranes has been tested in preclinical animal models and clinical trials. RESULTS: These two approaches have been demonstrated in phase II human trials to improve the survival of intensive care unit patients with AKI and multiorgan failure. The use of a 'smart' immunomodulatory membrane is also being evaluated in a small exploratory clinical trial to assess its effects on immunoregulation in ESRDpatients requiring chronic hemodialysis. CONCLUSIONS: The use of renal progenitor/stem cell therapy and/or cytopheretic membranes may result in effective treatments to alter the dysregulated immunological state of acute or chronic renal failure and improve the outcomes of these diseases. Copyright (c) 2010 S. Karger AG, Basel.
Authors: Christopher J Pino; Alexander S Yevzlin; Kyungsoo Lee; Angela J Westover; Peter L Smith; Deborah A Buffington; H David Humes Journal: Nephrol Dial Transplant Date: 2012-11-09 Impact factor: 5.992
Authors: Farah Tasnim; Rensheng Deng; Min Hu; Sean Liour; Yao Li; Ming Ni; Jackie Y Ying; Daniele Zink Journal: Fibrogenesis Tissue Repair Date: 2010-08-10
Authors: Feng Ding; Joon Ho Song; Ju Young Jung; Liandi Lou; Min Wang; Linda Charles; Angela Westover; Peter L Smith; Christopher J Pino; Deborah A Buffington; H David Humes Journal: PLoS One Date: 2011-04-14 Impact factor: 3.240
Authors: Thomas Rimmelé; Ata Murat Kaynar; Joseph N McLaughlin; Jeffery V Bishop; Morgan V Fedorchak; Anan Chuasuwan; Zhiyong Peng; Kai Singbartl; Daniel R Frederick; Lin Zhu; Melinda Carter; William J Federspiel; Adriana Zeevi; John A Kellum Journal: Crit Care Date: 2013-03-26 Impact factor: 9.097